- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 14:59 | Bayer trial combines two top drugs for kidney disease | ||
| 13:58 | Digital health firm Omada Health prices $150m IPO | ||
| 12:59 | AZ claims EU approval for new Calquence regimens in CLL | ||
| 10:59 | Wockhardt has high hopes for novel antibiotic Zaynich | ||
| Do | New auction for 23andMe sought with $305m bid from ex-CEO | ||
| Do | Has mRNA delivered a breakthrough in quest for HIV cure? | ||
| Do | NHS cleared to use Novo Nordisk's long-acting growth hormone | ||
| Do | MHRA advises contraception for women taking 'skinny jabs' | ||
| Do | EU: Trials should include pregnant subjects where possible | ||
| Do | Neuralink raises $650m to widen use of brain implants | ||
| Mi | Ascletis says oral acne drug shows "exceptional efficacy" | ||
| Mi | Hims & Hers buys Zava to form European beachhead | ||
| Mi | MSD rumoured to be eyeing $3bn+ MoonLake takeover | ||
| Mi | ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa | ||
| Mi | ASCO 25: J&J combo pill may see wider use in prostate cancer | ||
| Di | Amid staff cuts, FDA looks to AI to 'optimise' reviews | ||
| Di | ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer | ||
| Mo | Consolidation in psychedelics as atai pairs with Beckley | ||
| Mo | BioNTech flips its cancer bispecific to BMS for a big profit | ||
| Mo | ASCO 25: AZ pitches upfront oral SERD use in breast cancer | ||
| Mo | 23andMe founder isn't giving up her bid to regain control | ||
| Mo | Sanofi draws up $9.1bn plan to buy Blueprint Medicines | ||
| 30.05. | Summit shrugs off survival miss with its VEGF bispecific | ||
| 30.05. | Astellas adds to claudin clout with $1.3bn+ Evopoint deal | ||
| 30.05. | Roche builds case for MS drug with two-year efficacy data |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .